JIM MAZZO
EXECUTIVE CHAIRMAN
NEUROTECH PHARMACEUTICALS INC.
WHY: Notable business exec in OC’s ophthalmology industry and current executive chairman of retinal implant company.
IN THE NEWS: Neurotech Pharmaceuticals in March received FDA approval for its cell therapy implant called ENCELTO, a treatment for a neurodegenerative retinal disease; now available to U.S. patients. Also helped lead the search for Chapman University’s new president Matt Parlow, serving as vice chairman of Chapman board of trustees.
NOTABLE: Last year, stepped down as executive chairman of Texas-based Trukera Medical after it was acquired by Bausch + Lomb for an undisclosed amount. Also former CEO and president of Advanced Medical Optics, global president of Carl Zeiss Meditec AG and CEO of Allergan’s North American and European eyecare organizations. Founder and past chairman of Octane.
QUOTABLE: “The approval is a pivotal moment for Neurotech, not only for Neurotech but for physicians and patients.”
